Increased soluble interleukin-1 type II receptor concentrations in postoperative patients and in patients with sepsis syndrome.

Plasma interleukin-1 (IL-1) activity is modulated in part through the simultaneous appearance of several inhibitors of IL-1 action, including interleukin-1 receptor antagonist (IL-1ra) and the soluble IL-1 type II receptor (IL-1RII). However, little is known concerning the plasma appearance of these inhibitors in patients following operative trauma or those with sepsis syndrome. In the present report, plasma IL-1beta, IL-1ra, and soluble IL-1RI and IL-1RII concentrations were evaluated in 118 patients with sepsis syndrome or after elective operative trauma. Plasma concentrations of IL-1ra increased significantly following elective operative repair of thoraco-abdominal and abdominal aortic aneurysms, and after bowel resection for inflammatory bowel disease, but did not increase after laparoscopic cholecystectomy. Plasma IL-1ra levels were also elevated in patients with sepsis syndrome. In contrast, soluble IL-1RII levels were only increased in patients after operative repair of thoraco-abdominal aortic aneurysms and in sepsis syndrome, whereas concentrations were unaffected by the other more modest surgical procedures. Plasma IL-1RI concentrations decreased in all postoperative patients in the first 24 hours after surgery. We conclude that both plasma IL-1ra and soluble IL-1RII concentrations often increase in sepsis and following some operative trauma. Less severe operative trauma increases the plasma concentration of only IL-1ra, whereas both IL-1ra and soluble IL-1RII are increased in patients with sepsis syndrome or following thoraco-abdominal aneurysm repair.

[1]  W. Eling,et al.  Interleukin-1 (IL-1)-induced resistance to bacterial infection: role of the type I IL-1 receptor , 1995, Antimicrobial agents and chemotherapy.

[2]  L. Moldawer,et al.  INTERLEUKIN‐1 AND INTERLEUKIN‐1 ANTAGONISM IN SEPSIS, SYSTEMIC INFLAMMATORY RESPONSE SYNDROME, AND SEPTIC SHOCK , 1995, Shock.

[3]  S. Dower,et al.  Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. , 1994, Journal of immunology.

[4]  S. Dower,et al.  Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. , 1994, Journal of immunology.

[5]  S. Dower,et al.  The two interleukin-1 receptors play different roles in IL-1 actions. , 1994, Clinical immunology and immunopathology.

[6]  R. F. Johnston,et al.  Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial , 1994 .

[7]  F. Carli,et al.  Metabolic and inflammatory responses after open or laparoscopic cholecystectomy , 1994, The British journal of surgery.

[8]  T. Nevalainen,et al.  Group II phospholipase A2 in sera of febrile patients with microbiologically or clinically documented infections. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  D. Remick,et al.  Requirements for tumor necrosis factor-alpha and interleukin-1 in limb ischemia/reperfusion injury and associated lung injury. , 1993, The American journal of pathology.

[10]  A. Mantovani,et al.  Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. , 1993, Science.

[11]  M. Gayle,et al.  Interleukin 1 signaling occurs exclusively via the type I receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D. Remick,et al.  Tumor necrosis factor, interleukin 6, and the acute phase response following hepatic ischemia/reperfusion. , 1993, The Journal of surgical research.

[13]  P. Vadas,et al.  Induction of group II phospholipase A2 expression and pathogenesis of the sepsis syndrome. , 1993, Circulatory shock.

[14]  K. McIntyre,et al.  Interleukin 1: an important mediator of host resistance against Pneumocystis carinii , 1992, The Journal of experimental medicine.

[15]  L. Moldawer,et al.  Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. , 1992, Blood.

[16]  S. Suter,et al.  High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. , 1992, The American review of respiratory disease.

[17]  D. Remick,et al.  Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. , 1992, The Journal of clinical investigation.

[18]  L. Moldawer,et al.  Type I IL-1 receptor blockade exacerbates murine listeriosis. , 1992, Journal of immunology.

[19]  C. Dinarello,et al.  Interleukin-1 down-regulates gene and surface expression of interleukin-1 receptor type I by destabilizing its mRNA whereas interleukin-2 increases its expression. , 1992, Immunology.

[20]  C. Dinarello,et al.  Production of interleukin-1-receptor antagonist during experimental endotoxaemia , 1991, The Lancet.

[21]  C. Valeri,et al.  Role for tumor necrosis factor as mediator of lung injury following lower torso ischemia. , 1991, Journal of applied physiology.

[22]  C. Dinarello,et al.  A specific receptor antagonist for interleukin 1 prevents Escherichia coli‐induced shock in rabbits , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  R. Chanock,et al.  A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Robert C. Thompson,et al.  Interleukin-1 receptor antagonist reduces mortality from endotoxin shock , 1990, Nature.

[25]  D. Remick,et al.  Evidence for Tumor Necrosis Factor‐induced Pulmonary Microvascular Injury After Intestinal Ischemia—Reperfusion Injury , 1990, Annals of surgery.

[26]  R. Strieter,et al.  Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. , 1990, The Journal of clinical investigation.

[27]  Robert C. Thompson,et al.  Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor , 1990, Nature.

[28]  M. T. Brewer,et al.  Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist , 1990, Nature.

[29]  K. Kaffka,et al.  Two high-affinity interleukin 1 receptors represent separate gene products. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[30]  P. Brandtzaeg,et al.  Brief Definitive Report the Complex Pattern of Cytokines in Serum from Patients with Meningococcal Septic Shock Association between Interleukin 6, Interleukin 1, and Fatal Outcome , 2022 .

[31]  E. Girardin,et al.  Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. , 1988, The New England journal of medicine.

[32]  J. Meer,et al.  Interleukin-1 and related pro-inflammatory cytokines in the treatment of bacterial infections in neutropenic and non-neutropenic animals , 1994, Biotherapy.

[33]  D. Remick.  Lung and gut injury induced by tumour necrosis factor. , 1993, Research in immunology.

[34]  R. Tompkins,et al.  Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. , 1990, The Journal of infectious diseases.

[35]  P. Vadas,et al.  Pathogenesis of hypotension in septic shock: correlation of circulating phospholipase A2 levels with circulatory collapse. , 1988, Critical care medicine.

[36]  W. Jos.  A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal Gram-negative infection , 1988 .